Cempra to develop antibiotic solithromycin for pediatric use and biodefense
The fourth generation macrolide antibiotic is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. Cempra chief executive officer Prabhavathi Fernandes said BARDA has recognized